increase PCa risk up to 6-fold, are associated with poor disease outcomes, and are the most common PVs in individuals with PCa. 4 – 11 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for PCa recommend germline genetic testing for
Search Results
Pilot Trial of Streamlined Genetic Education and Traceback Genetic Testing in Prostate Cancer Survivors
Marc D. Schwartz, Beth N. Peshkin, Claudine Isaacs, Christopher Grisham, Nora J. Holmes, Lia J. Sorgen, Sean Collins, Nancy Dawson, Colleen McGuire, Tobechukwu Okobi, Kelsey Newell, Kavitha A. Kolla, and Veronique Weinstein
Laboratory Selection in Germline Genetic Testing: Laboratory Science Matters
Suzanne M. Mahon
Case Report A 41-year-old female underwent germline genetic testing ordered by her medical oncologist. Results showed that the patient tested negative for pathogenic variants in the following genes: APC , AXIN , BMPR1A , CDH1 , CHECK2
Racial Differences in Germline Genetic Testing Completion Among Males With Pancreatic, Breast, or Metastatic Prostate Cancers
Jeffrey W. Shevach, Danielle Candelieri-Surette, Julie A. Lynch, Rebecca A. Hubbard, Patrick R. Alba, Karen Glanz, Ravi B. Parikh, and Kara N. Maxwell
developing lethal cancers. Thus, germline genetic testing is now a guideline-recommended standard of care for a growing number of patients with specific cancer diagnoses. Genetic testing is indicated for all individuals assigned male sex at birth (herein
Risk Assessment, Genetic Testing, and Management of Lynch Syndrome
Shilpa Grover and Sapna Syngal
unclear pathogenic significance is found, genetic test results are considered indeterminate or uninformative. Individuals with indeterminate results are still considered at higher-than-average risk, and recommendations for surveillance must be based on
Referral, Uptake, and Outcome of Genetic Counseling and Testing in Patients With Early-Onset Colorectal Cancer
Hareem Syed, Joshua Sommovilla, Carol A. Burke, Sarah McGee, Carole Macaron, Brandie Heald, Ruishen Lyu, Stephanie L. Schmit, Kanika Nair, Suneel Kamath, Smitha Krishnamurthi, Alok A. Khorana, and David Liska
in 16% to 20% patients who have undergone genetic testing, and approximately half of these are found in genes associated with Lynch syndrome. 12 – 15 Population-based studies have shown that up to one-third of patients with PGVs do not meet genetic
The Future of Parallel Tumor and Germline Genetic Testing: Is There a Role for All Patients With Cancer?
Ying L. Liu and Zsofia K. Stadler
Historical Approaches to Genetic Testing in Cancer Although the inherited component of cancer susceptibility has been appreciated for decades, novel gene discoveries and new implications for therapeutics have highlighted its importance in modern
Interpretation of Genetic Testing for Lynch Syndrome in Patients With Putative Familial Colorectal Cancer
Christina Rybak and Michael J. Hall
cancers, polyposis, family history of syndrome-specific malignancies, and certain histologic features. In the absence of polyposis, the genetic testing algorithm for hereditary CRC focuses largely on identifying Lynch syndrome (LS), also known as
Current Insights: Evolving Principles and Controversies of Cancer Risk Assessment and Management of Hereditary Cancers
Presented by: Robert Pilarski, Jennifer M. Weiss, Susan M. Domchek, and Moderated by Tuya Pal
With the introduction of panel and direct-to-consumer (DTC) testing, genetic testing has become commonplace in recent years. Although this has paved the way for increased awareness around prevalent genetic cancer risks, it also allows for an
The Genetics of Hereditary Non-Polyposis Colorectal Cancer
Stephen B. Gruber and Wendy Kohlmann
Petersen GM . AGA technical review on hereditary colorectal cancer and genetic testing . Gastroenterology 2001 ; 121 : 198 – 213 . 8 Watson P Lynch HT . The tumor spectrum in HNPCC . Anticancer Res 1994 ; 14 : 1635 – 1639 . 9
Evaluating the NCCN Clinical Criteria for Recommending BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer
Caiqian Cropper, Ashley Woodson, Banu Arun, Carlos Barcenas, Jennifer Litton, Sarah Noblin, Diane Liu, Minjeong Park, and Molly Daniels
-cause mortality. 10 Throughout the past 20 years during which BRCA1/2 genetic testing has been clinically available, the question of who should be offered genetic testing has been debated. Because most breast cancer is not attributable to BRCA1/2 mutations
